ADRISK Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Aktiv)
CARE Carbon Ion Re-Radiotherapy in Patients With Recurrent or Progressive Locally Advanced Head-and-Neck Cancer (Aktiv)
CTNO155B12101 Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies (Aktiv)
GUARD Tissue Retractors for Radiation Therapy of Head and Neck Tumors (Aktiv)
KO-TIP-007 (AIM-HN/SEQ-HN) Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN) (Aktiv)
Proto-R-Schädelbasis Protonentherapie von Tumoren der Schädelbasis: Prospektive Erfassung von Effizienz und Nebenwirkungen bei klinischen Standarddosen (Aktiv)
Erstlinie
F-MISO-PET Evaluation of 18F-MISO-PET detectable changes in proliferation and dispersion of hypoxic subvolume in patients undergoing radio(chemo)therapy (Aktiv)
TopROC Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer (Aktiv)
Zweitlinie oder später
ADRISK Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Aktiv)
CNIR178X2201 Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)
ISA101b-OPC-03-19 Phase II Studie zur ISA101b Impfung als Zweitlinientherapie bei wiederkehrendem HPV16+ Oropharynxkarzinom (Aktiv)
LIBRETTO-001 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (Aktiv)